Advanced Bifurcation Systems (ABS), a clinical-stage medical device company with a patented bifurcation stenting platform to standardize the treatment of all bifurcation lesions in coronary angioplasties, is showcasing its innovative platform at the ABS booth at Transcatheter Cardiovascular Therapeutics (TCT). The platform features the only modular self-aligning stent technology to evenly scaffold bifurcations.

“Current statistics for bifurcation stenting show the highest stenting failure rates resulting in repeat revascularization procedures,” said Mehran Khorsandi, MD, interventional cardiologist and member of the HARTS stent team, Cedars-Sinai Medical Center, co-founder and CMO of ABS. “In the absence of an effective reproducible technology for addressing left main bifurcation disease, most patients are referred for open-heart surgery. The ABS technology overcomes the limitations of current approaches while simplifying the procedure.”

The ABS platform is a unique single system addressing main and side branches offering a disruptive bifurcation stenting technique that:

  • uses bifurcating stents deployed on a Mother/Daughter® (MD) monorail to branch and self-align covering bifurcations with no gaps;
  • uses a dual-catheter system to move stents into position in one continuous process;
  • eliminates gaps or overlaps and tangling of wires associated with current stent installations.

“Our stenting platform reduces the need for repeat procedures and enables effective bifurcation stenting treatment,” said ABS Chief Executive Officer Charles Laverty. “This simple procedure addresses a significant portion of patients who otherwise would be referred to open-heart surgery.”

ABS has filed a pre-submission with the FDA to define its clinical pathway leading to a PMA. The company also is defining its regulatory and clinical strategy for Europe to obtain a CE Mark.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here